This Week on NeurologyLive — February 1, 2021

Every week, the NeurologyLive staff prepares this preview of what to expect from our coverage. This week on NeurologyLive, there are a number of hot topics that we will be posting throughout the week. As always, our weekly coverage extends beyond just these topics, so make sure to check out the rest of the site!

This week, the latest episode of the NeurologyLive Cure Connections series, "The Multiple Sclerosis Patient Journey," will air. This group conversation is led by June Halper, MSN, MSCN, who is joined by Patricia K. Coyle, MD, and Frederick Foley, PhD, as well as patient and care partner Ann Moore and Kathy Zelles. They discuss the specifics of patients' journies with MS and offer their perspectives on various facets of the disease.

To catch up on the rest of the series, click here.

The latest in our NeuroVoices series, dedicated to conversations with leaders in the neurology community, will go live later this week. This time, our featured guests are Barbara Karp, MD, program director of the National Institute of Neurological Disorders and Stroke (NINDS), and Shannon Meropol, MD, assistant professor in the department of health at NYU Langone. They join the discussion this Wednesday, February 3, 2021, to discuss the recently launched database from the National Institutes of Health (NIH) to track neurological symptoms associated with COVID-19.

To check out the prior NeuroVoices conversations, click here.

A conversation with Julie Parsons, MD, Haberfeld Family Endowed Chair in Pediatric Neuromuscular Disorders, professor of clinical pediatrics and neurology, at Children’s Hospital Colorado and the University of Colorado School of Medicine, will air during NeurologyLive's segment on the Medical World News channel this Thursday, February 4, 2021. She offered insight into what she and her investigators in the phase 4 RESPOND trial of nusinersen (Spinraza; Biogen) are hoping to observe.

To check out what's on the Medical World News channel now, click here.

Also this week, the latest in our News Network series, "Treating Epilepsy: Key Takeaways From AES 2020," has aired, featuring Trevor Resnick, MD, who reviews the post-hoc analysis of a phase 3 open-label study on the impact of dose adjustments of concomitant antiseizure medications on the tolerability and retention of adjunctive cenobamate in uncontrolled focal seizures.

To check out the whole series, click here.

In that same vein, the American Epilepsy Society (AES) Annual Meeting may have wrapped up, but NeurologyLive's coverage is still ongoing! A number of expert interviews are still being conducted to learn and speak more about the data presented at the conference, as well as how the latest updates from the virtual conference floor are expected to impact clinical practice.

To catch up on post-AES 2020 coverage and expert perspectives, click here.